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and adjuvant (ABC) breast cancers as an example. METHODS:
Estimates of the combined ICUR and the economic value to
society (deﬁned as monetized cumulative net quality-adjusted life
years—QALYs—gained minus net treatment costs) created over
the product life cycle are based on projections of the annual
disease incidence of HER2+ ABC and MBC from launch in 1998
through patent expiry and projected ICURs in MBC and in ABC
over this period. Model assumes a U.S. perspective and lifetime
horizon for the CU models. All cost and outcomes are discounted
at 3% to 1998. RESULTS: We project that in 2016 the volume
of ABC treatment with H will be approximately 3 to 4 times that
of MBC. For MBC, the estimated ICUR is $95,500 (mean gain
= 0.5 QALYs); for ABC, the estimate is an ICUR of $26,417
(mean gain = 1.7 QALYs). Over the product life cycle, the overall
ICUR is $34,400 per QALY with a total of 465,000 discounted
QALYs gained. If these QALYs were valued at $50,000 or
$150,000, the projected economic value of H treatment would
range from $23 to $70 billion, respectively. CONCLUSIONS:
Using the case of trastuzumab, we show how the addition of the
ABC indication and the product life cycle approach affects the
overall economic impact. The indication-speciﬁc models used
typically do not account for the important interdependence of
drug development and adoption decisions over the life cycle. This
raises an important policy question about the meaning of the
“societal perspective” for drugs with multiple indications.
PCN60
ASSESSMENT OF THE COMPUTATIONAL INTELLIGENCE
BASED MODELS USEFULNESS FOR PHARMACOECONOMICS
NEEDS
Polak S1, Skowron A2, Mendyk A1, Brandys J1
1Jagiellonian University, Cracow, Malopolska, Poland, 2Jagiellonian
University, Cracow, Poland
OBJECTIVES: Modeling techniques are widely used in pharma-
coeconomics studies. Computational intelligence (CI) is an
example of modeling approach successfully applied in various
areas of science and technology. The aim of the study was to
assess the usefulness of CI tools in pharmacoeconomics analysis.
METHODS: Database contained 100 patients with Non-small
Cell Lung Cancer (NSCLC) in IIIB and IVth stage. Every patient
was described by 30 features (pharmacotherapy and diagnostics
path). The pharmacotherapy characteristics included chemother-
apy schemes based on cisplatin or carboplatin with vinorelbine,
gemcitabine, etoposide and the additive therapy. The output
value had binary characteristic (35 weeks of survival as a thresh-
old). Data Mining Software WEKA was used. Support vector
classiﬁer (SMO), naive Bayes classiﬁer (NB), and decision trees
(RandomForest, J48) were applied. The quality of models was
assessed based on their generalization abilities. The 10-fold cross
validation procedure was applied. RESULTS: The best results
obtained for each one of above mentioned tools were as follows:
SMO—80% of all positive, 70% of good positive and 86% of
good negative; NB—69%, 70%, 68%; RandomForest—75%,
68%, 79%; J48—74%, 57%, 84% respectively. Using best
obtained models, the in silico tests with various chemotherapy
schemes were applied. Simultaneously, the cost-effectiveness
studies with modeled survival were performed as the effective-
ness measure of simulated in silico chemotherapeutic schemes.
The results conﬁrm the literature information about the clinical
and economical efﬁcacy of abovementioned chemotherapy
schemes (i.e. no statistical signiﬁcance in clinical outputs between
vinorelbine—cis-platine and gemcitabine—cis-platine but the
vinorelbine based scheme was more cost-effective). The experi-
ment with in silico cytostatics dose reduction from 100% to 0
showed that BSC therapy could be the valuable alternative for
palliative chemotherapy. CONCLUSIONS: Computational intel-
ligence was found to be powerful and ﬂexible tool allowing reli-
able models creation to perform in silico search for optimal
therapy.
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OBJECTIVES: Follicular Lymphoma (FL) is the most common
type of indolent Non-Hodgkin Lymphoma, making up around
22% of all cases. It has an incidence of 13–15 cases per 100,000
(Olsen JH, 2005). A literature review revealed a paucity of
Quality of Life research in this area with no published utility
values. The objective of this study was to collect utility values
for active disease and remission health states for use in a health
economic model. METHODS: Patients with follicular lym-
phoma (n = 222) were recruited from 8 sites around the UK.
Utility scores were obtained using the EQ-5D questionnaire.
Patients were analysed according to 5 health states (newly diag-
nosed, relapsed, partial response to treatment, full response to
treatment/remission, and disease-free). These categories were
grouped to form two broader health states; ﬁrstly “progression-
free” which included patients experiencing partial or full
response to treatment and those categorised as disease-free; 
and secondly “progression” which included relapsed patients.
RESULTS: The results of this study show that the utility score
of an individual with follicular lymphoma differs according to
his or her disease state. The patients with the highest utility
scores were those who had experienced a full response to treat-
ment or who were categorised as “disease-free”. Those patients
who had the lowest utility were those who were categorised as
relapsed. Those patients who fell between these two groups were
those who were categorised as having partially responded to
treatment. CONCLUSIONS: Differences in utility were appar-
ent between patients in the 5 health states. These differences were
particularly highlighted when scores were grouped according to
“progression-free” and “progression” health states.
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